Evidence map›Paper›PMID 38649630›Full record

ReviewCurrent treatment options in oncology2024

Immunotherapy for Brain Tumors: Where We Have Been, and Where Do We Go From Here?

Alexander F Wang, Brian Hsueh, Bryan D Choi, Elizabeth R Gerstner, Gavin P Dunn

Abstract readReview
PubMed Publisher
In one paragraph

Review in Current treatment options in oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
3.5field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 8 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Alexander F WangDepartment of Neurosurgery, Massachusetts General Hospital, 55 Fruit Street, Boston, MA, 02114, USA.
Brian HsuehDepartment of Neurosurgery, Massachusetts General Hospital, 55 Fruit Street, Boston, MA, 02114, USA.
Bryan D ChoiDepartment of Neurosurgery, Massachusetts General Hospital, 55 Fruit Street, Boston, MA, 02114, USA.
Elizabeth R GerstnerDepartment of Neurology, Massachusetts General Hospital, Boston, MA, USA.
Gavin P DunnDepartment of Neurosurgery, Massachusetts General Hospital, 55 Fruit Street, Boston, MA, 02114, USA. gpdunn@mgh.harvard.edu.
Massachusetts General Hospital · USCenter for Neuro-Oncology · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

opinion statementImmunotherapy for glioblastoma (GBM) remains an intensive area of investigation. Given the seismic impact of cancer immunotherapy across a range of malignancies, there is optimism that harnessing the power of immunity will influence GBM as well. However, despite several phase 3 studies, there are still no FDA-approved immunotherapies for GBM. Importantly, the field has learned a great deal from the randomized studies to date. Today, we are continuing to better understand the disease-specific features of the microenvironment in GBM-as well as the exploitable antigenic characteristic of the tumor cells themselves-that are informing the next generation of immune-based therapeutic strategies. The coming phase of next-generation immunotherapies is thus poised to bring us closer to treatments that will improve the lives of patients with GBM.

Indexed as

Brain NeoplasmsImmunotherapyTumor MicroenvironmentClinical Trials as TopicCombined Modality TherapyDisease ManagementGlioblastomaHumansTreatment OutcomeFuture treatment optionsGlioblastomaImmunotherapy

Identifiers

PMID38649630
OpenAlexW4394992518

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.